# NCT01863550 (NCT01863550)

> Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01863550
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Plasma Cell Myeloma
- Interventions: Bortezomib; Carfilzomib; Dexamethasone; Laboratory Biomarker Analysis; Lenalidomide; Quality-of-Life Assessment
- Enrollment: 1087
- Primary outcome: Overall survival (OS) for the maintenance analysis
- Primary outcome: Progression-free survival for the induction analysis

## Commentary we found

- X threads: 16

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct01863550

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01863550", "email": "<work email>"}; the inbox owner confirms by the emailed link.